X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. It is being evaluated for the treatment of chronic inducible urticaria & symptomatic dermographism.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
Celldex intends to use the net proceeds from the offering to continue clinical and preclinical development of its product candidate CDX-0159 (barzolvolimab) KIT Antagonist mAb. It is being evaluated in patient for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $460.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 05, 2024
Details:
Celldex intends to use the net proceeds from the offering to continue clinical and preclinical development of its product candidate CDX-0159 (barzolvolimab) KIT Antagonist mAb. It is being evaluated in patient for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
Celldex intends to use the net proceeds from the offering to continue the clinical development of CDX-0159 (barzolvolimab), KIT Antagonist mAb. It is currently evaluated in the clinical trial studies for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2024
Details:
CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. It is being evaluated for the treatment of chronic spontaneous urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2024
Details:
The proceeds will continue development of Celldex's product, including current and future development of CDX-0159 (barzolvolimab), growing its bispecific antibody platform and clinical candidates, funding ongoing efforts to develop additional clinical pipeline.
Lead Product(s): Barzolvolimab
Therapeutic Area: Dermatology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $200.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Details:
The proceeds will continue development of Celldex's product, including current and future development of CDX-0159 (barzolvolimab), growing its bispecific antibody platform and clinical candidates, funding ongoing efforts to develop additional clinical pipeline.
Lead Product(s): Barzolvolimab
Therapeutic Area: Dermatology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Details:
CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is investigated for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. which is investigated for the treatment of Chronic Spontaneous Urticaria.
Lead Product(s): Barzolvolimab
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells.
Lead Product(s): Barzolvolimab
Therapeutic Area: Gastroenterology Product Name: CDX-0159
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
